India's CBI arrests Darwin Labs co-founder for the $2B GainBitcoin Ponzi scheme. Meanwhile, Bitcoin price faces bearish pressure near $65,000. The post GainBitcoinIndia's CBI arrests Darwin Labs co-founder for the $2B GainBitcoin Ponzi scheme. Meanwhile, Bitcoin price faces bearish pressure near $65,000. The post GainBitcoin

GainBitcoin Ponzi Scheme: India Arrests Suspect

2026/03/12 21:12
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

India’s Central Bureau of Investigation (CBI) has apprehended Ayush Varshney, the co-founder of Darwin Labs, for his alleged involvement in the multi-billion dollar GainBitcoin Ponzi scheme. Authorities intercepted Varshney at Mumbai airport on March 10 while he allegedly attempted to flee the country, marking a significant escalation in a case involving 29,000 mined bitcoins, valued today at over $2 billion.

While law enforcement tightens the net on historical crypto fraud cases, traders are currently navigating a bearish consolidation phase following a rejection from key resistance levels earlier this week.

DISCOVER: What is the Next Crypto to Explode in 2026?

CBI Arrests Suspect in GainBitcoin Ponzi Scheme

According to the CBI announcement, the GainBitcoin scheme was operated through Variabletech Pte. Ltd., which allegedly enticed investors with unsustainable promises of high returns on cryptocurrency deposits. Darwin Labs is accused of architecting the technological infrastructure that facilitated the fraud, including the proprietary MCAP token and various ERC-20 smart contracts.

Investigators claim the misappropriation extends beyond the initial token sales. The firm reportedly supported a network of ancillary platforms—including the GBMiners.com bitcoin mining pool and the CoinE Bank wallet—designed to simulate legitimate economic activity. Local reports indicate the scheme, which launched in 2015, siphoned roughly ₹19 crore ($2.1 million) in fiat currency alongside the massive haul of misappropriated Bitcoin.

Can Bitcoin Hold $69,000? Next Resistance is $72,000

Bitcoin price analysis

Bitcoin Price Analysis Source: TradingView

While regulators address the ghosts of the 2017 bull run, current market dynamics present immediate challenges for investors. Bitcoin is currently trading near $70,300, having surged approximately 1% in the last 24 hours. The asset recently faced a strong rejection at the $72,000 resistance level, a ceiling that has capped upside momentum throughout early March.

Technical analysis suggests a “path of least resistance” to the downside, with the asset slipping below its 50-week moving average. If the $69,000 support level fails, Bitcoin’s entire setup could become even weaker, potentially triggering a retest of the $60,000 level.

EXPLORE: Best New Cryptocurrencies in 2026 – Recently Launched Coins & Investment Watchlist

Regulatory Clarity Price Setup

The intersection of high-profile arrests and falling asset prices often creates a compounding effect on investor sentiment. However, the removal of bad actors like those alleged in the GainBitcoin ponzi scheme case is structurally bullish for the industry’s long-term maturity. As seen when Sam Bankman-Fried’s legal battles dominated headlines, the immediate price action often suffers from reputation damage before recovering on the promise of a cleaner market.

For the immediate term, Bitcoin remains tethered to macroeconomic data and technical supports. With the U.S. Dollar Index (DXY) strengthening slightly to 99.411, risk assets face headwinds. Investors are advised to watch the $68,000-$69,000 level closely; a clean break below could accelerate the bearish trend, while holding this zone may allow for consolidation before the next attempt at $72,000.

next

The post GainBitcoin Ponzi Scheme: India Arrests Suspect appeared first on Coinspeaker.

Market Opportunity
NEAR Logo
NEAR Price(NEAR)
$1.2593
$1.2593$1.2593
-2.10%
USD
NEAR (NEAR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Synopsys (SNPS) Stock — Elliott Investment Builds Multibillion-Dollar Stake

Synopsys (SNPS) Stock — Elliott Investment Builds Multibillion-Dollar Stake

TLDR Elliott Investment Management has built a multibillion-dollar stake in Synopsys (SNPS), per the WSJ. The activist firm wants Synopsys to generate more revenue
Share
Coincentral2026/03/23 17:00
Oil Demand Elasticity: Sobering Analysis Reveals Limited Price Relief Ahead – Societe Generale

Oil Demand Elasticity: Sobering Analysis Reveals Limited Price Relief Ahead – Societe Generale

BitcoinWorld Oil Demand Elasticity: Sobering Analysis Reveals Limited Price Relief Ahead – Societe Generale Global energy markets face a sobering reality in 2025
Share
bitcoinworld2026/03/23 17:05
Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

The post Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves appeared on BitcoinEthereumNews.com. The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee, America’s Health Insurance Plans said Wednesday, Sept. 17, 2025. In this photo is a free flu and Covid-19 vaccine shots available sign, CVS, Queens, New York. (Photo by: Lindsey Nicholson/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty Images The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee. The announcement by America’s Health Insurance Plans (AHIP), which includes CVS Health’s Aetna, Humana, Cigna, Centene and an array of Blue Cross and Blue Shield plans as members, comes ahead of the first meeting of the reconstituted Advisory Committee on Immunization Practices, which now has new members chosen by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine critic. “Health plans are committed to maintaining and ensuring affordable access to vaccines,” AHIP said in a statement Wednesday. “Health plan coverage decisions for immunizations are grounded in each plan’s ongoing, rigorous review of scientific and clinical evidence, and continual evaluation of multiple sources of data.” The move by AHIP is good news for millions of Americans at a time of year when they flock to drugstores, pharmacies, physician’s offices and outpatient clinics to get their seasonal flu and Covid shots. Kennedy’s changes to U.S. vaccine policy have created confusion across the country over whether certain vaccines long covered by insurance would continue to be. AHIP has now provided some clarity for millions of Americans. “Health plans will continue to cover all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing…
Share
BitcoinEthereumNews2025/09/18 03:11